Soligenix announced that the Office of Orphan Products Development of the United States FDA has granted orphan drug designation to the active ingredient in MarVax, the subunit protein vaccine of recombinantly expressed Marburg marburgvirus glycoprotein, for “the prevention and post-exposure prophylaxis against MARV infection.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNGX:
- Soligenix confirms FDA orphan designation for active ingredient in SuVax
- Soligenix prophylaxis against Sudan Ebola Virus gets FDA orphan designation
- Soligenix prevention against Marburg marburgvirus gets FDA orphan designation
- Soligenix reaches agreement with EMA on second HyBryte trial
- Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
